No abstract available
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adult
-
Antineoplastic Agents, Alkylating / adverse effects
-
Antineoplastic Agents, Alkylating / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / analysis
-
Blood Component Removal
-
Busulfan / administration & dosage
-
Busulfan / adverse effects
-
Busulfan / therapeutic use
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Combined Modality Therapy
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Female
-
Fusion Proteins, bcr-abl / analysis
-
Graft Survival
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Hematopoietic Stem Cell Mobilization / methods
-
Hematopoietic Stem Cell Transplantation* / adverse effects
-
Humans
-
Hydroxyurea / administration & dosage
-
Hydroxyurea / adverse effects
-
Hydroxyurea / therapeutic use
-
Ifosfamide / administration & dosage
-
Ifosfamide / adverse effects
-
Immunologic Factors / adverse effects
-
Immunologic Factors / therapeutic use
-
Interferon-alpha / adverse effects
-
Interferon-alpha / therapeutic use
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Male
-
Middle Aged
-
Transplantation Conditioning / adverse effects
-
Transplantation, Autologous
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Alkylating
-
Biomarkers, Tumor
-
Immunologic Factors
-
Interferon-alpha
-
Granulocyte Colony-Stimulating Factor
-
Etoposide
-
Fusion Proteins, bcr-abl
-
Busulfan
-
Cisplatin
-
Ifosfamide
-
Hydroxyurea